Insider buying last 90 days
No open-market insider purchases were filed for PGNY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PGNY insider filing, plotted on the chart in Gekko.Open PGNY in Gekko
NASDAQ: PGNY
Progyny (PGNY) Stock Analysis & Forecast
Oct 12 close
$28.03+0.10 (+0.4%)
Gekko Brief
AI summaryOct 12 closeProgyny shares advanced this week on optimism around its annual selling season, with the company announcing an expectation of adding 1.2 million new covered lives by the first half of 2027, a figure described as pacing toward a record level. Leerink Partners reiterated a Buy rating on the stock following the news, while Argus had lowered its rating on Progyny to Hold as of 30 September 2026. Coverage also framed Progyny against peer Charles River Laboratories on relative value grounds.
Progyny closed at $28.03, up 0.4%, sitting above both its 50-day average of $26.75 and its 200-day average of $24.23, with the shorter average above the longer one. The stock's one-month return stands at 2.5%, its six-month return at 65.1%, and its 52-week range spans $16.10 to $33.07. The GekkoIndex reads 51.4, placing it in the Neutral zone, down 9.3 over the past five sessions. Price sits 3.7% above Gekko Fair Value of $27.03.
Progyny next reports earnings on 5 November 2026 after close, 24 days away and within a typical 20-trading-day holding window; its last report showed EPS of $0.34 against an estimate of $0.28, with a 10.4% reaction. No insider, Congress, or unusual options activity appears in the respective windows. Seasonally, the next 20 trading days have averaged a 5.4% return over 5 years, rising in 3 of them. Analyst consensus across 10 firms includes 8 Buy and 2 Hold ratings, with a consensus target of $34.42.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Progyny price vs fair value
Close $28.03200-day averageGekko Fair Value $27.03
Progyny quick facts
- Market cap
- $2.20B
- P/E ratio
- 30.3
- Forward P/E
- 11.9
- EPS, TTM
- $0.92
- Revenue, TTM
- $1.31B
- Profit margin
- 6%
- Dividend yield
- —
- Beta
- 1.02
- Volume
- 825,981 avg 1.17M
- 1-year return
- +36.3%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±8.5%
- 50-day average
- $26.75
- 200-day average
- $24.23
- Next earnings
- Nov 5 after close
- Shares outstanding
- 76.73M
Progyny swing-trade checklist
Progyny scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $28.03 is above the 50-day ($26.75) and 200-day ($24.23) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.4, Neutral
Reading 51.4 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.7% above
Price is within 5% of Gekko Fair Value (3.7% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.4% on average
From this point in the calendar, the next 20 trading days averaged +5.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Progyny stock chart and price history
Progyny closed at $28.03 on Oct 12, 2026, +36.3% over the past year, inside a 52-week range of $16.10 to $33.07.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.5%
- 3 months
- −13.4%
- 6 months
- +65.1%
- 1 year
- +36.3%
The full PGNY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PGNY in Gekko
Follow Progyny through every session
Put PGNY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PGNY in GekkoFree for 7 days. No credit card required.
About Progyny
Progyny provides fertility and family-building benefits that employers offer to their workforces across the United States. Its main program combines a structured benefits plan with dedicated member support and access to a curated group of fertility specialists. The company is particularly recognized for this approach to managing fertility-related benefits on behalf of employers.
Beyond the core fertility plan, Progyny operates Progyny Rx, a pharmacy benefits service that helps members obtain the medications needed for their treatments. The company also runs reimbursement programs, sponsored by employers, that assist employees pursuing surrogacy or adoption. Its customers are therefore the employers who select and fund these benefit offerings for their employees.
Progyny was founded in 2008 and is headquartered in New York City. It was originally known as Auxogyn, Inc. before changing its name to Progyny, Inc. in 2015. The company's shares are listed on the NASDAQ under the ticker PGNY.
- Listed
- NASDAQ
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Website
- progyny.com
Progyny GekkoIndex: the smart money zone
Progyny’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.4, in the Neutral zone, down 9.3 points over five sessions.
51.4Neutral
Down 9.3 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 54 | +0.7% | −0.9% | ||
| Accumulation | 279 | +0.3% | +1.4% | ||
| Neutral (current zone) | 302 | −0.9% | −1.5% | ||
| Distribution | 46 | +4.0% | +2.7% | ||
| Selling | 1 | Too few readings yet | |||
Average PGNY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PGNY price, zone by zone.Track PGNY in Gekko
Is Progyny stock overvalued? Gekko Fair Value
Progyny trades 3.7% above Gekko Fair Value of $27.03, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Progyny shares are worth, recalculated every trading day.
$27.03
Gekko Fair Value, Oct 10, 2026
3.7% above fair value · About fair value
At the end of Aug 2026 the price was 9.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PGNY in Gekko
Progyny insider and Congress trading
No open-market insider purchases were filed for Progyny, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PGNY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PGNY, plotted on the chart in Gekko.Open PGNY in Gekko
Buybacks
Progyny has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $148.6M
- As a share of market cap
- 6.77%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold PGNY.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Progyny earnings: next date and track record
Progyny reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.31
- Revenue estimate
- $340.6M
8 of 8reports beat the EPS estimate
±13.2%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Progyny reported record Q2 2026 revenue, gross profit, and adjusted EBITDA with continued gross margin expansion and strong cash flow generation. The company is experiencing accelerating sales momentum with early client commitments and strong retention among largest clients, largely de-risking 2027 client turnover. Management attributes competitive strength to transparent reporting, demonstrated ROI, cost management, and member satisfaction metrics that competitors reportedly cannot match.
- Guidance
- Management provided Q3 and full-year 2026 financial outlook, citing favorable positioning entering the critical new client closing period. Strong retention and new sales momentum support expectations for another year of solid growth into 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.34 est $0.28 | $350.5M est $349.0M | −10.4% |
| May 7, 2026 | $0.29 est $0.26 | $328.5M est $326.5M | +26.8% |
| Feb 26, 2026 | $0.48 est $0.14 | $318.4M est $307.4M | −17.1% |
| Nov 6, 2025 | $0.45 est $0.39 | $313.3M est $314.3M | +18.5% |
| Aug 7, 2025 | $0.48 est $0.44 | $332.9M est $299.2M | −2.7% |
| May 8, 2025 | $0.48 est $0.45 | $324.0M est $307.8M | −9.5% |
| Feb 27, 2025 | $0.42 est $0.37 | $298.4M est $277.3M | −2.0% |
| Nov 12, 2024 | $0.40 est $0.13 | $286.6M est $277.1M | −18.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Progyny stock forecast and analyst price targets
Analysts’ average 12-month price target for Progyny is $34.42, +22.8% from the last close, from 10 firms rating the stock in the last 90 days.
$34.42consensus 12-month target, +22.8% from the last close
Now $28.03Avg $34.42
Low $30High $40
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | Canaccord Genuity | $35 | +24.9% |
| Oct 7 | Leerink Partners | — | — |
| Sep 8 | Citizens JMP | $33 | +17.7% |
| Aug 21 | J.P. Morgan | $30 | +7.0% |
| Aug 21 | J.P. Morgan | $30 | +7.0% |
−1.5%average 20-day move after past Neutral readings
+5.4%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Progyny seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Progyny averaged +5.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 2 of 5 |
| Next 10 trading days | −0.9% | 2 of 5 |
| Next 15 trading days | +0.4% | 2 of 5 |
| Next 20 trading days | +5.4% | 3 of 5 |
| Next 30 trading days | −0.7% | 1 of 5 |
For scale, PGNY’s typical 20-trading-day move in either direction is about 8.5%.
Progyny market cap and key statistics
Progyny’s market cap is $2.20B, with a P/E ratio of 30.3 and revenue of $1.31B over the last twelve months.
Valuation
- Market cap
- $2.20B
- P/E ratio
- 30.3
- Forward P/E
- 11.9
- EPS, TTM
- $0.92
- Gekko Fair Value
- $27.03
Trading
- Volume
- 825,981
- Avg volume, 20 days
- 1.17M
- 52-week high
- $33.07
- 52-week low
- $16.10
- Shares outstanding
- 76.73M
Financials
- Revenue, TTM
- $1.31B
- Profit margin
- 6%
- Return on equity
- 16.2%
- Quarterly earnings growth, YoY
- +78.9%
Risk and income
- Beta
- 1.02
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±8.5%
Progyny stock news this week
Coverage of Progyny this week reads positive: 6 positive, 1 neutral and 1 negative headlines.
- Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?Yahoo! Finance Canada, Oct 8
- Leerink Partners Maintains Progyny(PGNY.US) With Buy RatingMoomoo, Oct 8
- Progyny expects 1.2 million new covered lives in 2027Investing.com, Oct 7
- Progyny expects 1.2 million new covered lives in 2027 By Investing.comInvesting.com Nigeria, Oct 7
- PGNY or CRL: Which Is the Better Value Stock Right Now?Zacks Investment Research, Oct 7
- Progyny expects 1.2 million new covered lives in 2027 selling seasonStreetInsider, Oct 7
Progyny peers
Progyny’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Distribution | 25.9% above |
| CTASCintas | Neutral | 14.1% above |
| PYPLPayPal | Neutral | 0.8% below |
| XYZBlock | Neutral | 7.5% above |
| CPAYCorpay | Neutral | 17.5% below |
| FISVFiserv | Accumulation | 39.7% below |
A peer links to its own page where one exists.
Progyny stock FAQ
What is Progyny’s market cap?
Progyny’s market cap is $2.20B at the Oct 12, 2026 close of $28.03, with 76.73M shares outstanding. The shares trade on a P/E ratio of 30.3.
What is the Progyny stock forecast?
The consensus analyst 12-month price target for Progyny is $34.42, +22.8% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Progyny stock overvalued or undervalued?
On Gekko’s estimate Progyny is about fair value: the Oct 12, 2026 close of $28.03 is 3.7% above Gekko Fair Value of $27.03. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Progyny report earnings next?
Progyny is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.31 per share on revenue of $340.6M. Progyny beat the earnings estimate in 8 of its last 8 reports, moving 13.2% on average across the report.
What is Progyny’s 52-week high and low?
Progyny’s 52-week high is $33.07 and its 52-week low is $16.10; it closed at $28.03 on Oct 12, 2026, +36.3% over the past year. Over the last five years the shares peaked at $68.32 on Nov 5, 2021.
Is Progyny stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Progyny the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.